Clinical outcomes in patients with COVID-19 treated with tofacitinib
| All cases | <65 years old | >65 years old | |
| Population | |||
| Number of patents, n (%) | 320 (100) | 210 (66) | 110 (34) |
| Female, % | 50 | 46 | 57 |
| Mean age (range), years | 59 (22–96) | 52 (22–64) | 74 (65–96) |
| Mean treatment duration (range), days | 7 (1–18) | 6 (1–17) | 7 (1–18) |
| Dexamethasone, % | 30.0 | 30.0 | 30.0 |
| Disease (on admission) | |||
| Clinical severity, % | |||
| Mild | 4.7 | 3.8 | 6.4 |
| Moderate | 79.7 | 83.3 | 72.7 |
| Severe | 15.0 | 11.9 | 20.9 |
| Critical | 0.6 | 1.0 | 0.0 |
| Lung involvement, % | |||
| CT 0 | 0.0 | 0.0 | 0.0 |
| CT 1 | 10.9 | 10.0 | 12.7 |
| CT 2 | 65.0 | 68.6 | 58.2 |
| CT 3 | 22.8 | 20.0 | 28.2 |
| CT 4 | 1.3 | 1.4 | 0.9 |
| C reactive protein: clinically significant abnormality, % | 73 | 74 | 71 |
| Outcomes | |||
| Death, n (%) | 27 (8.4) | 5 (2.4) | 22 (20.0) |
| Mean days from hospitalisation till death (range), days | 13 (4–60) | 17 (9–34) | 12 (0–33) |
| ICU admission, n (%) | 65 (20) | 28 (13) | 37 (34) |
| Mean stay in ICU (range), days | 7 (1–28) | 7 (1–28) | 7 (1–24) |
| Mechanical ventilation, n (%) | 28 (8.8) | 11 (5.2) | 17 (15.5) |
| Mean duration of mechanical vent. (range), days | 5 (1–26) | 9 (1–26) | 3 (1–6) |
| Safety | |||
| Thromboses, n (%) | 7 (2.2) | 2 (1.0) | 5 (4.6) |
| Pulmonary embolism, n (%) | 3 (0.9) | 0 (0.0) | 3 (2.7) |
| Infectious complications, n (%) | 22 (6.9) | 9 (4.3) | 13 (11.8) |
ICU, intensive care unit.